403802-41-5

Upstream product

• 203664-61-3 4-(2,2-dibromo-vinyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 50-00-0 formaldehyd 

Downstream Products

• 1416366-38-5 tert-butyl 4-((1R,2R)-2-(((3-fluoro-4-(methylthio)benzyl)oxy)methyl)cyclopropyl)piperidine-1-carboxylate 
• 1416364-64-1 tert-butyl 4-((1R,2R)-2-(((3-fluoro-4-(methylsulfonyl)benzyl)oxy)methyl)cyclopropyl)piperidine-1-carboxylate 
• 1416366-42-1 tert-butyl 4-((1R,2R)-2-(((3,5-difluoro-4-(methylthio)benzyl)oxy)methyl)cyclopropyl)piperidine-1-carboxylate 
• 1416364-78-7 tert-butyl 4-((1R,2R)-2-(((3,5-difluoro-4-(methylsulfonyl)benzyl)oxy)methyl)cyclopropyl)piperidine-1-carboxylate 
• 1416366-45-4 4-[({(1R,2R)-2-[1-(tert-butoxycarbonyl)piperidin-4-yl]cyclopropyl}methoxy)methyl]-2-fluorobenzoic acid 
• 1416366-46-5 tert-butyl 4-((1R,2R)-2-{[(3-fluoro-4-{[methoxy(methyl)amino]carbonyl}benzyl)oxy]methyl}cyclopropyl)piperidine-1-carboxylate 
• 1416366-47-6 4-[({(1R,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}methoxy) methyl]-2-fluoro-N-methoxy-N-methylbenzamide 
• 1416364-85-6 4-[({(1R,2R)-2-[1-(5-chloropyrimidin-2-yl)piperidin-4-yl]cyclopropyl}methoxy) methyl]-2-fluorophenyl(cyclopropyl)methanone 
• 1416365-01-9 5-ethyl-2-{4-[(1R,2R)-2-((1S)-2-methoxy-1-{[4-(ethylsulfonyl)benzyl]oxy}ethyl)cyclopropyl]piperidin-1-yl}pyrimidine 
• 1416366-65-8 tert-butyl 4-[(1R,2R)-2-({[2-fluoro-4-(methylthio)benzyl]oxy}methyl)cyclopropyl]piperidine-1-carboxylate 
• 1416366-66-9 tert-butyl 4-[(1R,2R)-2-({[2-fluoro-4-(methylsulfonyl)benzyl]oxy}methyl)cyclopropyl]piperidine-1-carboxylate 
• 1416366-76-1 (2-(4-((1R,2R)-2-(((2-fluoro-4-(methylsulfonyl)benzyl)oxy)methyl)cyclopropyl)piperidin-1-yl)pyrimidin-5-yl)methanol 
• 1416365-74-6 2-(4-((1R,2R)-2-(((2-fluoro-4-(methylsulfonyl)benzyl)oxy)methyl)cyclopropyl)piperidin-1-yl)-5-(methoxymethyl)pyrimidine 
• 1416365-05-3 2-(4-((1R,2R)-2-(((2-fluoro-4-(methylsulfonyl)benzyl)oxy)methyl)cyclopropyl)piperidin-1-yl)pyrimidine-5-carbaldehyde 

Relevant academic research and scientific papers

GPR119 AGONISTS

This disclosure is directed, at least in part, to GPR119 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR119 agonists are gut-restricted compounds. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.

Design of Potent and Orally Active GPR119 Agonists for the Treatment of Type II Diabetes

We report herein the design and synthesis of a series of potent and selective GPR119 agonists. Our objective was to develop a GPR119 agonist with properties that were suitable for fixed-dose combination with a DPP4 inhibitor. Starting from a phenoxy analo

SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT

Substituted cyclopropyl compounds of the formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled rece

2,3-oxidosqualene-lanosterol cyclase inhibitors

The present invention relates to piperidine derivatives useful for the treatment and/or prophylaxis of diseases which are associated with 2,3-oxidosqualene-lanosterol cyclase such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, gallstones, tumors and/or hyperproliferative disorders, and treatment and/or prophylaxis of impaired glucose tolerance and diabetes.